Exceptions were the trial manager, study administrator, lifestyle counsellors, and participants who could not be blinded owing to the nature of the intervention.
The sole exception is the clinical trial of Engström et al 5 giving an outcome for prednisolone therapy of 72% (patients with a Sunnybrook score of 100) or 78% (HB I) for complete recovery after 12 months.
A notable exception is the positive correlation between trials to acquire a discrimination and trials to acquire its reversal observed in a recent study of song sparrows, Melospiza melodia (Boogert et al., 2011).
An important exception is the African American Heart Failure Trial (AHeFT), a well-designed, prospective, randomized, placebo-controlled, double-blind study, that added a combination of fixed-dose isosorbide dinitrate/hydralazine (ISDN/ HYD) to standard therapy and showed a 43% improvement in survival and a 33% reduction in first hospitalizations.
The exception was the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS), which failed to show a significant difference in the cardiovascular event incidence between treated and placebo patients (6).
The observed patterns were consistent across trials, with the only exception being the Italian phase 2 trial for women aged 35 to 60.
The exception was the post-consolidation randomisation of one trial [ 25].
The most notable exception was the percentage of patients in clinical trials (QI No. 8), which failed to achieve the DKG/DGS benchmark value (i.e. the 3rd-year FAB requirement) of 20% throughout the study period.
The exceptions were the few trials in which patients had very high cholesterol levels (greater than 9.0 mmol/L).
Upon reading of this petition and hearing of the application it was denied, and exception being noted, the trial proceeded.
